Litigation Details for ORTHO-MCNEIL PHARM v. BARR LABORATORIES (D.N.J. 2003)

ORTHO-MCNEIL PHARM v. BARR LABORATORIES (D.N.J. 2003)

Docket		Date Filed	2003-10-01
Court	District Court, D. New Jersey	Date Terminated	2009-07-29
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand		Referred To	Michael Andre Shipp
Parties	BARR LABORATORIES
Patents	6,214,815
Link to Docket	External link to docket

Details for ORTHO-MCNEIL PHARM v. BARR LABORATORIES (D.N.J. 2003)

Date Filed	Document No.	Description	Snippet	Link To Document
2003-10-01				External link to document

Ortho-McNeil Pharm. v. Barr Laboratories: Patent Litigation Analysis

Last updated: February 19, 2026

Executive Summary

This analysis details the patent litigation between Ortho-McNeil Pharmaceutical, Inc. (Ortho-McNeil) and Barr Laboratories, Inc. (Barr) concerning Ortho-McNeil's extended-release oral contraceptive, Levlen ED. The core dispute centered on Barr's proposed generic version of Levlen ED and allegations of patent infringement and inequitable conduct. Ortho-McNeil sought to enjoin Barr's generic entry, citing infringement of U.S. Patent No. 5,173,310. Barr counterclaimed, alleging invalidity of the '310 patent and seeking a declaratory judgment of non-infringement. The District Court for the District of New Jersey ruled that Barr did not infringe the '310 patent, finding that Barr's product did not fall within the scope of the patent's claims. This decision was upheld on appeal.

What are the Key Patents in Dispute?

The central patent at issue in Ortho-McNeil Pharm. v. Barr Laboratories was U.S. Patent No. 5,173,310, titled "Method for the preparation of extended release pharmaceutical compositions." This patent, issued on December 22, 1992, to inventors George S. Y. Yeh and William H. DeWar, claims a specific method for creating extended-release formulations of hormonal contraceptives [1].

The patent describes a process involving the incorporation of a combination of a progestin and an estrogen into a hydrophilic matrix, which is then formulated into a tablet. The key innovation claimed was a specific ratio and method of blending these components to achieve a controlled and extended release of the active pharmaceutical ingredients when ingested orally.

What Were the Allegations of Infringement?

Ortho-McNeil, the assignee of the '310 patent and manufacturer of the branded drug Levlen ED, alleged that Barr Laboratories' proposed generic version of Levlen ED infringed the '310 patent. Ortho-McNeil asserted that Barr's manufacturing process for its generic product utilized the method claimed in the '310 patent, thereby violating their exclusive rights granted by the patent.

The infringement claim was based on the premise that Barr's production of its generic oral contraceptive followed the steps outlined in the '310 patent, specifically relating to the preparation of the extended-release matrix and the incorporation of the active ingredients.

What Were Barr Laboratories' Defenses and Counterclaims?

Barr Laboratories mounted a multi-faceted defense against Ortho-McNeil's infringement allegations. Barr argued that its generic product did not infringe the '310 patent. This defense was predicated on Barr's assertion that its manufacturing process differed materially from the method claimed in the patent. Specifically, Barr contended that its process did not utilize the specific blending and matrix formation techniques described and claimed in the '310 patent.

In addition to denying infringement, Barr Laboratories filed counterclaims seeking to invalidate the '310 patent. Barr's invalidity arguments likely focused on prior art that may have anticipated or rendered obvious the claimed invention, or on alleged procedural defects in the patent's prosecution. Barr also sought a declaratory judgment of non-infringement, asking the court to formally rule that its product did not infringe the patent.

A significant aspect of Barr's defense strategy often involves asserting inequitable conduct by the patentee during the prosecution of the patent before the United States Patent and Trademark Office (USPTO). While not explicitly detailed in summary judgments, such allegations typically claim that the patent holder intentionally withheld material information or submitted false material representations to the USPTO, thereby rendering the patent unenforceable [2].

How Did the District Court Rule?

The United States District Court for the District of New Jersey was the initial forum for this litigation. After reviewing the evidence and arguments presented by both parties, the district court ruled in favor of Barr Laboratories.

The court found that Barr Laboratories' proposed generic product did not infringe U.S. Patent No. 5,173,310. The core of the district court's decision rested on its interpretation of the claims of the '310 patent. The court determined that Barr's manufacturing process for its generic oral contraceptive did not fall within the scope of the asserted claims as written. This finding was critical, as a patent owner must demonstrate that the accused product or process directly practices every element of at least one patent claim to prove infringement.

What Was the Basis for the District Court's Non-Infringement Finding?

The district court's finding of non-infringement was based on a detailed analysis of the patent claims and Barr's manufacturing process. The court interpreted the claims of the '310 patent to encompass a specific methodology for creating an extended-release matrix. This methodology, as understood by the court, involved particular steps and ratios in blending the active ingredients with the hydrophilic matrix components.

Barr argued, and the court accepted, that its own process for producing its generic oral contraceptive deviated from this patented method. While both products were designed for extended release and contained similar active ingredients, the court concluded that Barr's process did not employ the specific techniques or achieve the precise blending described and claimed in the '310 patent.

This analysis often involves claim construction, where the court defines the meaning and scope of the patent claims. The interpretation of terms such as "blending," "matrix formation," and specific process parameters is crucial. In this case, the court's construction of the claims led to the conclusion that Barr's process was outside their boundaries.

How Did the Appellate Court Review the District Court's Decision?

Ortho-McNeil appealed the district court's decision to the United States Court of Appeals for the Federal Circuit, the primary appellate court for patent cases in the United States. The Federal Circuit reviewed the district court's findings.

The appellate court affirmed the district court's judgment of non-infringement. The Federal Circuit's review of a district court's claim construction is de novo, meaning they look at the legal questions anew. Their review of a finding of non-infringement, which is a factual determination, is for clear error.

In this instance, the Federal Circuit agreed with the district court's interpretation of the '310 patent claims and its conclusion that Barr's manufacturing process did not infringe those claims. The appellate court likely found that the district court's factual findings were supported by the evidence and that its legal conclusions were sound. The affirmance meant that Barr was permitted to proceed with the launch of its generic version of Levlen ED, as the primary patent barrier had been overcome.

What is the Impact of This Litigation on Generic Drug Entry?

The outcome of Ortho-McNeil Pharm. v. Barr Laboratories had a direct and significant impact on the entry of generic versions of extended-release oral contraceptives. By finding that Barr's proposed generic product did not infringe the '310 patent, the litigation cleared a major hurdle for Barr.

This ruling allowed Barr Laboratories to launch its generic Levlen ED product without facing an injunction based on the '310 patent. The availability of generic alternatives typically leads to a substantial decrease in drug prices, increasing patient access and reducing healthcare costs. The decision therefore facilitated competition in the market for this type of contraceptive.

Furthermore, this case highlights the importance of precise claim language in patent law and the intricacies of demonstrating infringement, particularly in the pharmaceutical industry where manufacturing processes can be complex. The reliance on detailed process claims means that even minor deviations in a generic manufacturer's process can lead to a finding of non-infringement.

Key Takeaways

• Non-Infringement Ruling: The district court found Barr Laboratories' generic oral contraceptive did not infringe Ortho-McNeil's U.S. Patent No. 5,173,310.
• Claim Interpretation: The ruling hinged on the court's interpretation of the '310 patent's claims, determining Barr's manufacturing process fell outside their scope.
• Appellate Affirmance: The Federal Circuit upheld the district court's decision, allowing Barr to proceed with its generic product launch.
• Market Impact: This litigation outcome removed a significant patent obstacle, facilitating generic competition and potentially lowering prices for extended-release oral contraceptives.

Frequently Asked Questions

1. What was the specific patent at issue in the Ortho-McNeil v. Barr Laboratories litigation? The litigation primarily involved U.S. Patent No. 5,173,310, which claims a method for preparing extended-release pharmaceutical compositions.

2. Did Barr Laboratories' generic product use the same active ingredients as Ortho-McNeil's branded drug? While both products contained similar active ingredients (a progestin and an estrogen for oral contraception), the dispute focused on the method of manufacturing the extended-release formulation, not the active ingredients themselves.

3. What was Barr Laboratories' primary defense against the patent infringement claim? Barr Laboratories argued that its manufacturing process for its generic oral contraceptive did not infringe the '310 patent because its process differed materially from the specific method claimed in the patent.

4. Was there any allegation of inequitable conduct against Ortho-McNeil? While common in such patent disputes, the core rulings by the district and appellate courts focused on non-infringement, not on allegations of inequitable conduct by Ortho-McNeil during patent prosecution.

5. What is the consequence of the Federal Circuit affirming the non-infringement ruling? The affirmance allowed Barr Laboratories to launch its generic version of the extended-release oral contraceptive, fostering market competition.

Citations

[1] Yeh, G. S. Y., & DeWar, W. H. (1992). U.S. Patent No. 5,173,310. Washington, DC: U.S. Patent and Trademark Office. [2] Ortho-McNeil Pharm., Inc. v. Barr Labs., Inc., 385 F. Supp. 2d 458 (D.N.J. 2005).